



**Nexstim Plc: Shares subscribed for based on Offer Warrant Plan 2019 have been registered**

*Company announcement, Helsinki, 8 November at 9 am (EET)*

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announced on 6 November 2019 that an aggregate of 10,511,689 new shares of Nexstim were subscribed for based on the exercise of the Offer Warrants under the Warrant Plan 2019. Such new shares have today been registered with the Trade Register.

Pursuant to the registration of the shares issued under Warrant Plan 2019 with the Trade Register, the number of shares in the Company is 45,912,562.

The trading of the new shares registered will begin approximately on 11 November 2019 in Nasdaq First North Growth Market Finland and approximately on 12 November 2019 in Nasdaq First North Growth Market Sweden.

NEXSTIM PLC

Martin Jamieson, CEO

**Further information is available on the website [www.nexstim.com](http://www.nexstim.com), or by contacting:**

**Martin Jamieson, Chairman and CEO**

+44 771 516 3942

[martin.jamieson@nexstim.com](mailto:martin.jamieson@nexstim.com)

**Sisu Partners Oy (Certified Adviser)**

Jussi Majamaa

+ 358 40 842 4479

[jussi.majamaa@sisupartners.com](mailto:jussi.majamaa@sisupartners.com)

**About Nexstim Plc**

Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

SmartFocus® technology is used in Nexstim's proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated

# Nexstim

TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information please visit [www.nexstim.com](http://www.nexstim.com)